XML 16 R7.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Non-Controlling Interest
Beginning balance (in shares) at Dec. 31, 2021   282,526,719        
Beginning balance at Dec. 31, 2021 $ 409,222 $ 2,825 $ 937,805 $ (91,774) $ (439,634)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 112,061       112,061  
Other comprehensive income 2,643     2,643    
Dividends declared (17,031)       (17,031)  
Shares issued in connection with deferred compensation plan, net (in shares)   3,425,795        
Shares issued in connection with deferred compensation plan (24,246) $ 34 (26)   (24,254)  
Deferred compensation plan elective participant deferrals 3,108   3,108      
Shares issued in connection with executive bonus plan, net (in shares)   159,797        
Shares issued in connection with executive bonus plan 6,696 $ 2 11,891   (5,197)  
Shares issued in connection with employee stock purchase plan (in shares)   109,749        
Shares issued in connection with employee stock purchase plan 4,490 $ 1 4,610   (121)  
Stock option exercises, net (in shares)   2,054,585        
Stock option exercises, net (2,539) $ 21 5,840   (8,400)  
Acquisition option exercises, net (in shares)   185,178        
Acquisition option exercises, net 0 $ 2 (2)      
Shares issued for stock grants, net (in shares)   13,632        
Shares issued for stock grants, net 450   450      
Stock-based compensation expense 17,529   17,529      
Shares related to restricted stock, net (in shares)   141,705        
Shares related to restricted stock, net (2,148) $ 2 (2)   (2,148)  
Repurchase of Class B Common Stock under approved program (in shares)   (463,001)        
Repurchase of Class B Common Stock under approved program (13,242) $ (5)     (13,237)  
Ending balance (in shares) at Jun. 30, 2022   288,154,159        
Ending balance at Jun. 30, 2022 496,993 $ 2,882 981,203 (89,131) (397,961)  
Beginning balance (in shares) at Mar. 31, 2022   285,134,093        
Beginning balance at Mar. 31, 2022 457,653 $ 2,851 957,498 (75,324) (427,372)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 55,673       55,673  
Other comprehensive income (13,807)     (13,807)    
Dividends declared (8,678)       (8,678)  
Shares issued in connection with deferred compensation plan, net (in shares)   2,616,044        
Shares issued in connection with deferred compensation plan 0 $ 26 (26)      
Deferred compensation plan elective participant deferrals 2,439   2,439      
Shares issued in connection with executive bonus plan, net (in shares)   87,692        
Shares issued in connection with executive bonus plan 3,892 $ 1 6,896   (3,005)  
Stock option exercises, net (in shares)   653,336        
Stock option exercises, net 2,344 $ 7 3,086   (749)  
Acquisition option exercises, net (in shares)   35,323        
Acquisition option exercises, net 0 $ 1 (1)      
Shares issued for stock grants, net (in shares)   13,632        
Shares issued for stock grants, net 450   450      
Stock-based compensation expense 10,862   10,862      
Shares related to restricted stock, net (in shares)   77,040        
Shares related to restricted stock, net (593) $ 1 (1)   (593)  
Repurchase of Class B Common Stock under approved program (in shares)   (463,001)        
Repurchase of Class B Common Stock under approved program (13,242) $ (5)     (13,237)  
Ending balance (in shares) at Jun. 30, 2022   288,154,159        
Ending balance at Jun. 30, 2022 496,993 $ 2,882 981,203 (89,131) (397,961)  
Beginning balance (in shares) at Dec. 31, 2022   289,014,487        
Beginning balance at Dec. 31, 2022 573,454 $ 2,890 1,030,466 (89,740) (370,866) $ 704
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 94,175       94,175  
Other comprehensive income 1,912     1,912    
Dividends declared (29,224)       (29,224)  
Shares issued in connection with deferred compensation plan, net (in shares)   2,782,181        
Shares issued in connection with deferred compensation plan (36,329) $ 28 (28)   (36,329)  
Deferred compensation plan elective participant deferrals 1,651   1,651      
Shares issued in connection with executive bonus plan, net (in shares)   137,197        
Shares issued in connection with executive bonus plan 5,480 $ 2 9,804   (4,326)  
Shares issued in connection with employee stock purchase plan (in shares)   153,381        
Shares issued in connection with employee stock purchase plan 4,335 $ 1 4,556   (222)  
Stock option exercises, net (in shares)   2,236,827        
Stock option exercises, net 3,711 $ 22 9,678   (5,989)  
Shares issued for stock grants, net (in shares)   12,639        
Shares issued for stock grants, net 600   600      
Stock-based compensation expense 28,343   28,343      
Shares related to restricted stock, net (in shares)   376,271        
Shares related to restricted stock, net (4,336) $ 4 (4)   (4,336)  
Ending balance (in shares) at Jun. 30, 2023   294,712,983        
Ending balance at Jun. 30, 2023 643,772 $ 2,947 1,085,066 (87,828) (357,117) 704
Beginning balance (in shares) at Mar. 31, 2023   291,501,271        
Beginning balance at Mar. 31, 2023 614,190 $ 2,915 1,060,842 (89,374) (360,897) 704
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 48,685       48,685  
Other comprehensive income 1,546     1,546    
Dividends declared (14,702)       (14,702)  
Shares issued in connection with deferred compensation plan, net (in shares)   1,729,443        
Shares issued in connection with deferred compensation plan (22,703) $ 17 (17)   (22,703)  
Deferred compensation plan elective participant deferrals 118   118      
Shares issued in connection with executive bonus plan, net (in shares)   57,393        
Shares issued in connection with executive bonus plan 2,421 $ 1 4,321   (1,901)  
Stock option exercises, net (in shares)   1,308,527        
Stock option exercises, net 1,210 $ 13 5,485   (4,288)  
Shares issued for stock grants, net (in shares)   12,639        
Shares issued for stock grants, net 600   600      
Stock-based compensation expense 13,718   13,718      
Shares related to restricted stock, net (in shares)   103,710        
Shares related to restricted stock, net (1,311) $ 1 (1)   (1,311)  
Ending balance (in shares) at Jun. 30, 2023   294,712,983        
Ending balance at Jun. 30, 2023 $ 643,772 $ 2,947 $ 1,085,066 $ (87,828) $ (357,117) $ 704